Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Quinidine-enhanced beta-blockade during treatment with propafenone in extensive metabolizer human subjects.

Clinical pharmacology and therapeutics - 1 Jan 1994

Mörike K E, Roden D M

Abstract excerpt

Propafenone, a sodium channel blocking antiarrhythmic drug with beta-blocking properties, is metabolized to non-beta-blocking metabolites in part by cytochrome P4502D6. Subtherapeutic doses of quinidine inhibit P4502D6 and increase plasma propafenone in extensive metabolizer subjects, in whom the active enzyme is present. In this study we tested the hypothesis that quinidine would enhance beta-blockade in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2D6
Share to Cytochrome P-450 Enzyme System
Share to Double-Blind Method

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Synergism

Share to Heart Rate

Share to Mixed Function Oxygenases

Share to Phenotype

Share to Stereoisomerism

Source

Identifiers

PMID: 7905369
DOI: 10.1038/clpt.1994.6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Quinidine-enhanced beta-blockade during treatment with propafenone in extensive metabolizer human subjects.PMID 7905369Read ↗

The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone.Semantic proximity Read ↗

Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings.Semantic proximity Read ↗

The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine.Semantic proximity Read ↗

Combined administration of quinidine and propafenone for atrial fibrillation: the CAQ-PAF study.Semantic proximity Read ↗

Simultaneous modeling of pharmacokinetics and pharmacodynamics of propafenone in healthy subjects.Semantic proximity Read ↗

Impact of CYP2D6 poor metabolizer phenotype on propranolol pharmacokinetics and response.Semantic proximity Read ↗

Clinical implications of variable antiarrhythmic drug metabolism.Semantic proximity Read ↗

Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects.Semantic proximity Read ↗

The influence of CYP2D6 polymorphism on the antiarrhythmic efficacy of propafenone in patients with paroxysmal atrial fibrillation during 3 months propafenone prophylactic treatment.Semantic proximity Read ↗

Effect of CYP2D6 genetic polymorphism on peak propafenone concentration: no significant effect of CYP2D6*10.Semantic proximity Read ↗

Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction.Semantic proximity Read ↗

Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.